Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Clinical trial NCT06686394 · RECRUITING
Trial details
- NCT number
- NCT06686394
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-26
- Primary completion
- 2030-04-18
- Enrollment
- 81
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.